<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ProstNFound+: A Prospective Study using Medical Foundation Models for Prostate Cancer Detection - Health AI Hub</title>
    <meta name="description" content="ProstNFound+ introduces a novel medical foundation model specifically adapted for prostate cancer detection using micro-ultrasound, demonstrating robust general">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>ProstNFound+: A Prospective Study using Medical Foundation Models for Prostate Cancer Detection</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2510.26703v1" target="_blank">2510.26703v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-10-30
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Paul F. R. Wilson, Mohamed Harmanani, Minh Nguyen Nhat To, Amoon Jamzad, Tarek Elghareb, Zhuoxin Guo, Adam Kinnaird, Brian Wodlinger, Purang Abolmaesumi, Parvin Mousavi
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> eess.IV, cs.CV
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2510.26703v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2510.26703v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">ProstNFound+ introduces a novel medical foundation model specifically adapted for prostate cancer detection using micro-ultrasound, demonstrating robust generalization in its initial prospective clinical validation. The model effectively integrates clinical biomarkers to provide interpretable heatmaps and risk scores for clinically significant PCa, showing consistent performance and strong alignment with established clinical protocols.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research pioneers the prospective clinical application of AI-driven medical foundation models for prostate cancer diagnosis using micro-ultrasound, offering a scalable, interpretable, and potentially more consistent method to identify clinically significant disease compared to current expert-dependent protocols.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper describes ProstNFound+, a medical foundation model designed to detect clinically significant prostate cancer from micro-ultrasound images. It functions by incorporating clinical biomarkers and generating interpretable cancer heatmaps and risk scores, serving as an AI-driven diagnostic assistance tool to augment or offer an alternative to expert-driven protocols in a clinical setting.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>ProstNFound+ is an adaptation of medical foundation models (FMs) designed for prostate cancer (PCa) detection using micro-ultrasound (¬µUS) images.</li>
                    
                    <li>The model architecture incorporates a medical FM, adapter tuning, and a custom prompt encoder for embedding PCa-specific clinical biomarkers, generating a cancer heatmap and a risk score for clinically significant PCa.</li>
                    
                    <li>Following training on multi-center retrospective data, ProstNFound+ underwent its first prospective validation on data acquired five years later from a new, independent clinical site.</li>
                    
                    <li>Prospective evaluation demonstrated strong generalization to the new data, showing no performance degradation compared to retrospective results.</li>
                    
                    <li>Model predictions, including risk scores and interpretable heatmaps, closely aligned with standard clinical scoring protocols (PRI-MUS and PI-RADS) and were consistent with biopsy-confirmed lesions.</li>
                    
                    <li>The study highlights ProstNFound+'s potential for clinical deployment as a scalable and interpretable alternative to current expert-driven PCa detection protocols.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>ProstNFound+ utilizes a medical foundation model architecture, enhanced with adapter tuning and a custom prompt encoder to integrate prostate cancer-specific clinical biomarkers. It was trained on multi-center retrospective data and prospectively evaluated on new data acquired five years later from a different clinical site. Model predictions (cancer heatmaps, risk scores for clinically significant PCa) were benchmarked against standard clinical scoring protocols (PRI-MUS and PI-RADS).</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The model demonstrated robust generalization to prospective data without any performance degradation compared to retrospective evaluation. Its generated cancer heatmaps were interpretable and consistent with biopsy-confirmed lesions, and its risk scores aligned closely with established clinical scoring systems like PRI-MUS and PI-RADS.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The successful prospective validation of ProstNFound+ suggests its potential for clinical deployment as a scalable, interpretable, and potentially standardized alternative for prostate cancer detection from micro-ultrasound, reducing reliance on highly specialized expert interpretation and potentially improving diagnostic consistency.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly stated in the provided abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly detailed in the abstract, though the conclusion implies future efforts would focus on actual clinical deployment and integration of the system into healthcare workflows.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Urology</span>
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Diagnostic Imaging</span>
                    
                    <span class="tag">Medical Artificial Intelligence</span>
                    
                    <span class="tag">Radiology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Prostate Cancer</span>
                    
                    <span class="tag tag-keyword">Micro-ultrasound</span>
                    
                    <span class="tag tag-keyword">Medical Foundation Models</span>
                    
                    <span class="tag tag-keyword">AI</span>
                    
                    <span class="tag tag-keyword">Diagnostic Systems</span>
                    
                    <span class="tag tag-keyword">Prospective Study</span>
                    
                    <span class="tag tag-keyword">Clinical Biomarkers</span>
                    
                    <span class="tag tag-keyword">Machine Learning</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Purpose: Medical foundation models (FMs) offer a path to build
high-performance diagnostic systems. However, their application to prostate
cancer (PCa) detection from micro-ultrasound ({\mu}US) remains untested in
clinical settings. We present ProstNFound+, an adaptation of FMs for PCa
detection from {\mu}US, along with its first prospective validation. Methods:
ProstNFound+ incorporates a medical FM, adapter tuning, and a custom prompt
encoder that embeds PCa-specific clinical biomarkers. The model generates a
cancer heatmap and a risk score for clinically significant PCa. Following
training on multi-center retrospective data, the model is prospectively
evaluated on data acquired five years later from a new clinical site. Model
predictions are benchmarked against standard clinical scoring protocols
(PRI-MUS and PI-RADS). Results: ProstNFound+ shows strong generalization to the
prospective data, with no performance degradation compared to retrospective
evaluation. It aligns closely with clinical scores and produces interpretable
heatmaps consistent with biopsy-confirmed lesions. Conclusion: The results
highlight its potential for clinical deployment, offering a scalable and
interpretable alternative to expert-driven protocols.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>